The Uromigos

This episode critically examines a recent Nature Medicine paper on the timing of immune therapy infusion in lung cancer, exploring the scientific plausibility, methodological concerns, and implications for future research. Tom, Brian and David McDermott debate the validity of the findings, the review process, and the need for rigorous prospective trials.

Summary
This Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group criteria, highlighting the iterative process of developing guidelines that reflect the latest scientific evidence and clinical practices. The speakers discuss the new PCWG4 including new nomenclature, the role of imaging technologies like PSMA PET, and the importance of biomarkers and patient-reported outcomes in enhancing patient care and treatment efficacy. They emphasize the collaborative nature of the working groups and the ongoing need for adaptation in response to emerging data and technologies.

3人で前立腺癌、腎癌、尿路上皮癌の2025をレビューしました。

In this podcast , the Uromigos discuss the upcoming ASCO GU conference. They delve into the latest research findings, including phase 3 trials, combination therapies, and the significance of biomarkers in treatment. The conversation highlights the importance of belzutifan in kidney cancer and explores the evolving landscape of prostate and bladder cancer treatments. The hosts also share their predictions and insights on how these developments may impact clinical practice.

In this Uromigos podcast episode, Brian and Tom engage with Elaine Chang from the FDA to discuss an analysis of depth of response as an indicator of survival in kidney cancer trials. They explore the FDA's data analysis process, the significance of tumor shrinkage, and the implications of their findings on treatment outcomes. The conversation delves into the limitations of current measurement methods and the potential for using depth of response as an early signal in drug development.